What is Dianthus Therapeutics's return on equity?

Dianthus Therapeutics (DNTH) reported return on equity of -28.6% in Q3 2025.

How has Dianthus Therapeutics's return on equity changed year-over-year?

Dianthus Therapeutics's return on equity decreased by 9.9% year-over-year, from -26% to -28.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Dianthus Therapeutics DNTH Return on equity

Return on equity at other companies

Johnson & JohnsonJNJ

26.4%-3.0pp

AmgenAMGN

101.3%-4.4pp

Spyre Therapeutics, Inc.SYRE

-31.1%-10.7pp

Kymera TherapeuticsKYMR

-27.1%-3.7pp

Protagonist TherapeuticsPTGX

-17.1%-26.1pp

TG TherapeuticsTGTX

112.6%+92.9pp

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Enterprise value$3.88B+565%

P/S1,465.1×+962×

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

net income/total stockholders equity=-28.6%

Based on trailing twelve months.

The official record: Dianthus Therapeutics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's return on equity?: Dianthus Therapeutics (DNTH) reported return on equity of -28.6% in Q3 2025.
How has Dianthus Therapeutics's return on equity changed year-over-year?: Dianthus Therapeutics's return on equity decreased by 9.9% year-over-year, from -26% to -28.6%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.